Special Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked Burden
We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these ...
12 Touko 30min
Special Edition: What's Next—Once-Weekly Insulin
In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approve...
5 Touko 20min
Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!
Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic d...
1 Touko 36min
Special Edition: What's Next—Emerging Technologies for People with Diabetes
In this special edition on Emerging Technologies for People with Diabetes our host, Dr. Neil Skolnik will discuss recent and future advances in technologies for people with diabetes. This special epis...
15 Huhti 35min
The Points of CARE - James Gavin & Naunihal Virdi on CGM Use in Noninsulin-Treated Patients, Ivy Shi & Dhruv Kazi on GLP-1 RA Eligibility in Reproductive-Age US Women, and Eva Tseng on START Diabetes Prevention
With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...
8 Huhti 30min
Special Edition - Continuous Ketone Monitoring April 2026
In this special edition on Continuous Ketone Monitoring our host, Dr. Neil Skolnik will discuss this new technology – its promise and its application. This special episode is supported by an independe...
7 Huhti 26min
Diabetes Core Update – April 2026
This issue will review: 1. Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide 2. Estimated Optimal Individualized Diabetes Risk Prediction From Preventive Interventions in the...
1 Huhti 26min
